Psychiatric Digital Biomarkers Market Size & Growth Forecast 2027–2036, By Segments (Type, Clinical Practice, End-use), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growth Outlook
Psychiatric Digital Biomarkers Market size was more than USD 942.1 million in 2026 and is set to grow at a 23.18% CAGR between 2027 and 2036, attaining USD 7.58 billion by 2036. The industry revenue for 2027 is estimated at USD 1.13 billion.
Get more details on this report
Request Free Sample ReportPsychiatric Digital Biomarkers Market Intelligence Snapshot
Regional Market Dynamics
- North America leads with 61.32% share due to a mature digital health ecosystem, strong integration of remote monitoring into clinical workflows, and widespread use of connected mental health platforms.
- Asia Pacific is the fastest-growing region at 26.07% CAGR, driven by rising smartphone and wearable penetration enabling continuous symptom tracking, remote engagement, and scalable mental health services.
Segment Momentum
- Wearable devices accounted for 42.29% of the market in 2026 because they enable continuous passive data collection and real-world behavioral monitoring with minimal patient effort, supporting sustained psychiatric assessment.
- Monitoring psychiatric digital biomarkers are growing fastest as care increasingly emphasizes continuous symptom tracking, treatment response, and relapse monitoring, creating stronger demand for longitudinal patient observation beyond initial diagnosis.
Market Expansion Drivers
- Rising mental health disorder prevalence accelerating demand for continuous digital monitoring solutions.
- Growing wearable device and mobile health app adoption expanding psychiatric biomarker data collection.
- AI-driven behavioral analytics improving early detection and personalized mental healthcare interventions.
Leading Market Participants
- Prominent companies in the psychiatric digital biomarkers market include Koneksa Health, Inc. (United States), Empatica Inc. (United States), VivoSense, Inc. (United States), IXICO plc (United Kingdom), Sonde Health, Inc. (United States), Clario (United States), Biogen Inc. (United States), Altoida, Inc. (United States), Mindstrong Health, Inc. (United States), Holmusk Technologies Pte. Ltd. (Singapore).
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 942.1 million
- 2027 Estimated Market Size: USD 1.13 billion.
- Projected Market Size: USD 7.58 billion by 2036
- Growth Forecast: 23.18% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: Wearable (Type) | Diagnostic Psychiatric Digital Biomarkers (Clinical Practice) | Healthcare Companies (End-use)
- Emerging Opportunity Segment: Mobile Based Applications (Type) | Monitoring Psychiatric Digital Biomarkers (Clinical Practice) | Payers (End-use)
Market Growth Drivers and Industry Trends
Rising mental health disorder prevalence accelerating demand for continuous digital monitoring solutions
The increasing prevalence of mental health conditions is creating demand for more continuous and objective approaches to understanding changes in patient behavior and symptoms. The psychiatric digital biomarkers market will gain momentum as digital monitoring technologies enable the collection of behavioral, physiological, and activity-related indicators outside conventional clinical encounters. Data derived from smartphone interactions, sleep patterns, movement, communication behavior, and other digitally captured signals can provide additional information about changes in an individual's condition between appointments. Continuous monitoring can also help clinicians observe symptom trajectories and treatment responses over time, complementing information obtained through traditional assessments and patient-reported outcomes.
Growing wearable device and mobile health app adoption expanding psychiatric biomarker data collection
Increasing use of connected wearable devices and mobile health applications is creating broader opportunities to capture behavioral and physiological information in everyday environments. Expansion of the psychiatric digital biomarkers market is being supported by the ability of smartphones, smartwatches, fitness trackers, and health applications to collect data related to sleep, physical activity, heart rate patterns, and daily behavioral changes. These technologies can facilitate repeated data collection without requiring patients to remain in clinical settings, providing researchers and healthcare professionals with longitudinal information that may be relevant to psychiatric assessment. Wider consumer familiarity with digital health platforms is also making technology-enabled monitoring more practical for research studies and remote care models.
AI-driven behavioral analytics improving early detection and personalized mental healthcare interventions
AI-based analytical systems can process large volumes of behavioral and physiological information to identify patterns that may be difficult to recognize through conventional clinical observation alone. The psychiatric digital biomarkers market is being strengthened by AI-driven analytics that can help detect deviations in sleep, activity, communication, and other behavioral signals associated with changes in mental health status. Advanced algorithms can support risk stratification and identify patterns that warrant closer clinical evaluation, while longitudinal analysis can provide additional context for monitoring individual responses to therapy. Integration of machine learning with digital biomarker platforms also enables more individualized interpretation of patient data, supporting personalized intervention strategies and ongoing treatment monitoring.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Rising mental health disorder prevalence accelerating demand for continuous digital monitoring solutions | 2.00% | High | North America, Europe | High | Near Term |
| Growing wearable device and mobile health app adoption expanding psychiatric biomarker data collection | 1.80% | Moderate | North America, Asia Pacific | High | Mid Term |
| AI-driven behavioral analytics improving early detection and personalized mental healthcare interventions | 1.50% | Moderate | Europe, North America | Emerging | Mid Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
North America (Largest Region)
North America dominated the psychiatric digital biomarkers market in 2026 with a 61.32% share, reflecting strong adoption of digital health technologies, advanced mental healthcare infrastructure, and increasing interest in objective approaches to psychiatric assessment. The region has a favorable environment for integrating data generated through smartphones, wearable devices, and other digital platforms into clinical research and patient monitoring. Growing recognition of the limitations of conventional subjective assessments is encouraging interest in measurable behavioral and physiological indicators. Investments in digital healthcare, expanding mental health research capabilities, and increasing use of technology-enabled monitoring are further supporting regional demand.
Asia Pacific (Fastest-Growing Region)
Asia Pacific is poised to be the fastest-growing region in the psychiatric digital biomarkers market, supported by expanding digital healthcare ecosystems, rising mental health awareness, and increasing access to connected technologies. Greater smartphone and wearable adoption is creating opportunities for continuous collection of behavioral and physiological data outside traditional clinical settings. Healthcare systems are also placing greater emphasis on improving psychiatric diagnosis, monitoring, and personalized care, creating demand for technology-enabled assessment tools. Increasing research activity and digital transformation across healthcare are expected to accelerate the integration of psychiatric digital biomarkers into clinical and research applications.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
Germany 🇩🇪
Clinical Validation FocusGermany emphasizes clinically validated psychiatric digital biomarkers that align with evidence-based mental healthcare and digital health regulations. Research institutions and healthcare providers in Germany are strengthening collaborations to improve the adoption of objective digital assessment tools within psychiatric practice.
France 🇫🇷
Data-Driven Mental CareFrance is encouraging the use of psychiatric digital biomarkers within research and clinical settings to improve objective mental health evaluation. Healthcare organizations in France are focusing on secure data collection and validated digital assessment methods that support routine psychiatric decision-making.
Italy 🇮🇹
Digital Psychiatry AdoptionItaly is incorporating psychiatric digital biomarkers into broader digital health initiatives aimed at improving mental healthcare delivery. Clinical centers in Italy are expanding the use of remote monitoring technologies that provide continuous patient insights and support individualized treatment planning.
Japan 🇯🇵
Remote Behavioral MonitoringJapan is expanding the use of psychiatric digital biomarkers to support continuous patient monitoring and address growing mental healthcare needs. Healthcare organizations in Japan are evaluating digital platforms that combine behavioral data with clinical workflows to improve long-term patient management.
South Korea 🇰🇷
AI-Enabled Psychiatric AssessmentSouth Korea is integrating artificial intelligence with digital biomarker platforms to strengthen psychiatric assessment and patient monitoring. Healthcare providers in South Korea continue adopting connected digital health solutions that support earlier intervention and more personalized mental health management.
United States 🇺🇸
Digital Mental Health IntegrationThe U.S. psychiatric digital biomarkers market is advancing through the integration of wearable devices, smartphone-based monitoring, and AI-supported analytics into behavioral health programs. Healthcare providers in the U.S. are prioritizing clinically validated digital tools that complement diagnosis, treatment monitoring, and personalized psychiatric care.
Segment Leadership and Growth Trends
Psychiatric Digital Biomarkers Market Share (%), by Type, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportType Segment Analysis: Wearable (Largest Segment) vs Mobile Based Applications (Fastest-Growing Segment)
Wearable devices held the largest share of the psychiatric digital biomarkers market in 2026, accounting for 42.29%, as continuous physiological and behavioral data collection becomes increasingly important in psychiatric assessment and monitoring. Wearables can capture signals associated with activity, sleep, physiological patterns, and other behavioral indicators, supporting more continuous observation than conventional episodic assessments. Growing interest in objective, real-world data and technology-enabled mental health monitoring is strengthening adoption, while improvements in sensor capabilities and device integration are broadening their clinical and research applications.
Mobile based applications represent the fastest-growing type segment, driven by the widespread accessibility of smartphones and the growing use of digital platforms for behavioral data collection and patient engagement. These applications can facilitate frequent data capture, symptom tracking, and remote interaction, supporting more flexible approaches to psychiatric monitoring. Increasing emphasis on accessible digital care, longitudinal observation, and convenient patient participation is creating favorable conditions for broader adoption of mobile-based digital biomarkers.
Clinical Practice Segment Analysis: Diagnostic Psychiatric Digital Biomarkers (Largest Segment) vs Monitoring Psychiatric Digital Biomarkers (Fastest-Growing Segment)
Diagnostic psychiatric digital biomarkers dominated the psychiatric digital biomarkers market in 2026, representing 33.07% of the market, as healthcare stakeholders increasingly seek objective digital indicators to complement conventional psychiatric assessment. These biomarkers can support the identification and characterization of behavioral or physiological patterns associated with psychiatric conditions, helping clinicians strengthen evidence-based evaluation. Growing interest in data-driven diagnosis and the integration of digital measurements into clinical workflows is supporting continued adoption of diagnostic applications.
Monitoring psychiatric digital biomarkers are expanding at the fastest pace as continuous assessment becomes increasingly relevant for understanding changes in symptoms and patient behavior over time. Digital monitoring can provide more frequent insights between clinical encounters, supporting individualized care and ongoing evaluation. Increasing adoption of remote healthcare approaches, patient-centered monitoring, and technology-enabled longitudinal assessment is strengthening demand for monitoring-oriented psychiatric digital biomarkers.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Type | Wearable, Mobile Based Applications, Sensors, Others | Wearable | Mobile Based Applications |
| Clinical Practice | Diagnostic Psychiatric Digital Biomarkers, Monitoring Psychiatric Digital Biomarkers, Predictive and Prognostic Psychiatric Digital Biomarkers, Others | Diagnostic Psychiatric Digital Biomarkers | Monitoring Psychiatric Digital Biomarkers |
| End-use | Healthcare Companies, Healthcare Providers, Payers, Others | Healthcare Companies | Payers |
Competitive Landscape and Market Positioning
Prominent players in the psychiatric digital biomarkers market:
1. Koneksa Health Inc. (United States)
2. Empatica Inc. (United States)
3. VivoSense Inc. (United States)
4. IXICO plc (United Kingdom)
5. Sonde Health Inc. (United States)
6. Clario (United States)
7. Biogen Inc. (United States)
8. Altoida Inc. (United States)
9. Mindstrong Health Inc. (United States)
10. Holmusk Technologies Pte. Ltd. (Singapore)
The psychiatric digital biomarkers market is progressing through the integration of artificial intelligence, wearable technologies, and behavioral data analytics. Research initiatives are increasingly focused on improving early detection, continuous monitoring, and personalized mental health assessment tools. Strategic collaborations between digital health innovators and clinical research organizations are further accelerating technological development and expanding application potential.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| Koneksa Health Inc. (United States) | |||||||
| Empatica Inc. (United States) | |||||||
| VivoSense Inc. (United States) | |||||||
| IXICO plc (United Kingdom) | |||||||
| Sonde Health Inc. (United States) | |||||||
| Clario (United States) | |||||||
| Biogen Inc. (United States) | |||||||
| Altoida Inc. (United States) | |||||||
| Mindstrong Health Inc. (United States) | |||||||
| Holmusk Technologies Pte. Ltd. (Singapore). |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| Beacon Biosignals | Apr-24 | Beacon Biosignals partnered with Takeda to utilize its FDA-cleared EEG headband and AI-driven analytics platform in sleep disorder clinical trials. This collaboration enables the collection of high-fidelity, laboratory-grade sleep data directly from patients' homes, significantly enhancing the ability to objectively monitor treatment efficacy and advance the adoption of digital biomarkers in CNS-related therapeutic development. |
| Tris Pharma | Apr-24 | Tris Pharma partnered with Braingaze Ltd. to launch Tris Digital Health, a dedicated business unit focused on digital therapeutics and diagnostics for ADHD and other neurological conditions. This move reflects a strategic shift toward integrating objective, gaze-tracking digital biomarkers into the diagnosis and management of neurodevelopmental disorders, aiming to improve therapeutic precision and patient-specific treatment protocols. |
| Indivi | Mar-24 | Indivi entered a multi-year partnership with Biogen to license the Konectom™ smartphone-based platform for neurological research. By integrating this technology with its dreaMS™ platform, Indivi is developing advanced digital endpoints for Parkinson’s disease, leveraging machine learning to derive precise, objective measures of disease progression that improve upon traditional, subjective clinical assessment tools in neuroscience R&D. |
| Empatica | Feb-24 | Empatica was selected as a technology partner by the U.S. Department of Defense (DoD) for the Defense Health Agency’s PTSD Drug Treatment Program. By deploying its wearable monitoring technology to gather physiological data, the company supports the development of objective biomarkers for tracking stress and treatment responses, reinforcing the utility of continuous physiological monitoring in complex mental health clinical trials. |
| Koneksa Health | Feb-22 | Koneksa Health secured USD 45 million in Series C funding to accelerate the development of its digital biomarker platform and clinical data integration capabilities. The investment supports the expansion of its clinical-grade sensor network and data analytics infrastructure, which enables pharmaceutical companies to collect real-time behavioral and physiological data, reducing clinical trial costs and improving patient stratification. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
Psychiatric Digital Biomarkers Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Disease Area | Mood Disorders, Schizophrenia and Psychotic Disorders, Anxiety and Obsessive-Compulsive Disorders, Trauma- and Stressor-Related Disorders, Neurodevelopmental Disorders, Substance Use Disorders |
| Deployment Model | Cloud-Based, On-Premise, Hybrid |
| Business Model | Software Licensing, Subscription-Based, Fee-for-Service, Enterprise Solutions |
Psychiatric Digital Biomarkers Market — Custom TOC
| Custom Chapter | Custom Details |
|---|---|
| Digital Biomarker Validation Landscape |
|
| Clinical Trial Integration Opportunities |
|
| Healthcare Provider Implementation Strategy |
|
Need a different cut of the data?
Request Custom ResearchHow big is the psychiatric digital biomarkers market?
How will the psychiatric digital biomarkers industry grow in terms of size and CAGR by 2036?
How is continuous digital monitoring reshaping care delivery in the psychiatric digital biomarkers market?
Why is AI becoming a key growth driver in the psychiatric digital biomarkers market?
Why are wearable devices the largest type segment in the psychiatric digital biomarkers market?
Why are monitoring psychiatric digital biomarkers emerging as the fastest-growing clinical practice segment?
Why is North America leading the psychiatric digital biomarkers market?
What is driving the fastest growth in Asia Pacific’s psychiatric digital biomarkers market?
Who are the major participants shaping the psychiatric digital biomarkers landscape?
Our Clients
"The team took the time to understand our specific business needs and delivered a report that was well aligned with our objectives. Their expertise and understanding of the industry were clearly reflected in the quality and relevance of the insights provided."
Siemens Healthcare
"Our experience in acquiring the research report has been excellent. The depth of analysis, and actionable insights provided have been extremely valuable in supporting our ongoing R&D efforts."
GC Biopharma
"The report offered a comprehensive view of the market trends. The in-depth segmentation and analysis of emerging opportunities gave us a better understanding of the market."
Medtronic
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Domains
10 coverage areasResearch Intelligence
| Source | Reference |
|---|---|
| World Health Organization (WHO) | www.who.int |
| U.S. Food & Drug Administration (FDA) | www.fda.gov |
| European Medicines Agency (EMA) | www.ema.europa.eu |
| Centers for Disease Control and Prevention (CDC) | www.cdc.gov |
| National Institutes of Health (NIH) | www.nih.gov |
| National Center for Biotechnology Information (NCBI) | www.ncbi.nlm.nih.gov |
| PubMed | pubmed.ncbi.nlm.nih.gov |
| ClinicalTrials.gov | clinicaltrials.gov |
| International Organization for Standardization (ISO) | www.iso.org |
| ASTM International | www.astm.org |
| Advanced Medical Technology Association (AdvaMed) | www.advamed.org |
| Medical Device Innovation Consortium (MDIC) | mdic.org |
| Biotechnology Innovation Organization (BIO) | www.bio.org |
| International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) | www.ifpma.org |
| U.S. Pharmacopeia (USP) | www.usp.org |
| European Directorate for the Quality of Medicines & HealthCare (EDQM) | www.edqm.eu |
| World Organisation for Animal Health (WOAH) | www.woah.org |
| American Hospital Association (AHA) | www.aha.org |
| OECD Health | www.oecd.org/health |
| World Bank Data | data.worldbank.org |
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization